Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218
Angeles Alvarez Secord(Duke University), Andrew B. Nixon(Duke University), Keiichi Fujiwara(Saitama Medical University), Wei Deng(Wuhan University), Kouros Owzar(Duke University), Jamie N. Bakkum‐Gamez(Mayo Clinic in Arizona), Heather A. Lankes(Nationwide Children's Hospital), Yingmiao Liu(Duke Medical Center), Herbert I. Hurwitz(Duke Medical Center), Krishnansu S. Tewari(University of California, Irvine Medical Center), Robert A. Burger(Mersana Therapeutics (United States)), Heidi J. Gray(Seattle Cancer Care Alliance), Robert S. Mannel(University of Oklahoma Health Sciences Center), Mark D. Starr(Duke Medical Center), Matthew Boente(Minnesota Oncology), Kirsten B. Burdett(Northwestern University), David Tritchler(Ontario Institute for Cancer Research), Michael J. Birrer(University of Arkansas Medical Center), David M. O’Malley(The Ohio State University), John C. Brady(Duke Medical Center), Alexander B. Sibley(Duke University)
Cited by 57
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k